PPARA Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid

The cardiovascular benefits of fibrates have been shown to be heterogeneous and to depend on the presence of atherogenic dyslipidemia. We investigated whether genetic variability in the PPARA gene, coding for the pharmacological target of fibrates (PPAR-α), could be used to improve the selection of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Diabetes
Main Authors: Morieri, Mario Luca, Shah, Hetal S., Sjaarda, Jennifer, Lenzini, Petra A., Campbell, Hannah, Motsinger-Reif, Alison A., Gao, He, Lovato, Laura, Prudente, Sabrina, Pandolfi, Assunta, Pezzolesi, Marcus G., Sigal, Ronald J., Paré, Guillaume, Marcovina, Santica M., Rotroff, Daniel M., Patorno, Elisabetta, Mercuri, Luana, Trischitta, Vincenzo, Chew, Emily Y., Kraft, Peter, Buse, John B., Wagner, Michael J., Cresci, Sharon, Gerstein, Hertzel C., Ginsberg, Henry N., Mychaleckyj, Josyf C., Doria, Alessandro
Formato: Artigo
Idioma:Inglês
Publicado em: American Diabetes Association 2020
Assuntos:
Genetics/Genomes/Proteomics/Metabolomics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7085251/
https://ncbi.nlm.nih.gov/pubmed/31974142
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/db19-0973
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados